Shares of Vericel Co. (NASDAQ:VCEL – Get Free Report) gapped down prior to trading on Wednesday . The stock had previously closed at $58.67, but opened at $55.09. Vericel shares last traded at $54.98, with a volume of 255,029 shares trading hands.
Analyst Ratings Changes
VCEL has been the subject of several recent research reports. BTIG Research increased their price target on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. Truist Financial raised their target price on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. HC Wainwright reaffirmed a “buy” rating and set a $60.00 target price on shares of Vericel in a research note on Wednesday. Stephens reaffirmed an “overweight” rating and set a $65.00 target price on shares of Vericel in a research note on Wednesday. Finally, StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a research note on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $62.14.
Get Our Latest Analysis on VCEL
Vericel Price Performance
Vericel (NASDAQ:VCEL – Get Free Report) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03. Vericel had a return on equity of 1.48% and a net margin of 1.56%. The company had revenue of $57.91 million for the quarter, compared to analyst estimates of $55.32 million. Equities analysts predict that Vericel Co. will post 0.13 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Robert L. Md Zerbe sold 2,500 shares of Vericel stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $60.00, for a total transaction of $150,000.00. Following the sale, the director now directly owns 26,595 shares in the company, valued at approximately $1,595,700. This trade represents a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jonathan Mark Hopper sold 10,000 shares of Vericel stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $58.72, for a total value of $587,200.00. Following the sale, the insider now owns 58,371 shares in the company, valued at $3,427,545.12. This trade represents a 14.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 15,100 shares of company stock worth $889,872 over the last 90 days. 7.20% of the stock is currently owned by corporate insiders.
Institutional Trading of Vericel
A number of hedge funds have recently bought and sold shares of VCEL. International Assets Investment Management LLC lifted its holdings in Vericel by 4,126.7% during the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after acquiring an additional 619 shares during the period. Farther Finance Advisors LLC raised its stake in shares of Vericel by 48.1% in the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock valued at $53,000 after buying an additional 405 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Vericel by 22.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock valued at $77,000 after purchasing an additional 322 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Vericel in the third quarter valued at $92,000. Finally, Quantbot Technologies LP purchased a new position in shares of Vericel in the third quarter valued at $146,000.
Vericel Company Profile
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
See Also
- Five stocks we like better than Vericel
- What is a Special Dividend?
- Top Growth Picks: 3 Low-Cost Stocks That Could Double in Value
- NYSE Stocks Give Investors a Variety of Quality OptionsÂ
- Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
- How to Find Undervalued Stocks
- Buffett’s Sale of BAC Stock: A Smart Move or Missed Opportunity?
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.